PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.

Abstract To investigate the effect of distant metastases sites on survival in patients with de novo stage-IV breast cancer. From 2010 to 2013, patients with a diagnosis of de novo stage-IV breast cancer were identified using the Surveillance, Epidemiology, and End Results database. Univariate and multivariate Cox regression analyses were performed to analyze the effect of distant metastases sites on breast cancer-specific survival and overall survival. A total of 7575 patients were identified. The most common metastatic sites were bone, followed by lung, liver, and brain. Patients with hormone receptor+/human epidermal growth factor receptor 2- and hormone receptor+/human epidermal growth factor receptor 2+ status were more prone to bone metastases. Lung and brain metastases were common in hormone receptor-/human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2- subtypes, and patients with hormone receptor+/ human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2+ subtypes were more prone to liver metastases. Patients with liver and brain metastases had unfavorable prognosis for breast cancer-specific survival and overall survival, whereas bone and lung metastases had no effect on patient survival in multivariate analyses. The hormone receptor-/human epidermal growth factor receptor 2- subtype conferred a significantly poorer outcome in terms of breast cancer-specific survival and overall survival. hormone receptor+/human epidermal growth factor receptor 2+ disease was associated with the best prognosis in terms of breast cancer-specific survival and overall survival. Patients with liver and brain metastases were more likely to experience poor prognosis for breast cancer-specific survival and overall survival by various breast cancer subtypes. Distant metastases sites have differential impact on clinical outcomes in stage-IV breast cancer. Follow-up screening for brain and liver metastases might be effective in improving breast cancer-specific survival and overall survival.
PMID
Related Publications

Optimal surveillance for postoperative metastasis in breast cancer patients.

Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.

Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.

Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment.

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Authors

Mayor MeshTerms
Keywords

Breast cancer

Epidemiology

Surveillance

and End Results

metastases

subtype

survival

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28653887
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - The effect of distant metastases sites on survival in de novo stage-IV breast
      cancer: A SEER database analysis.
PG  - 1010428317705082
LID - 10.1177/1010428317705082 [doi]
AB  - To investigate the effect of distant metastases sites on survival in patients
      with de novo stage-IV breast cancer. From 2010 to 2013, patients with a diagnosis
      of de novo stage-IV breast cancer were identified using the Surveillance,
      Epidemiology, and End Results database. Univariate and multivariate Cox
      regression analyses were performed to analyze the effect of distant metastases
      sites on breast cancer-specific survival and overall survival. A total of 7575
      patients were identified. The most common metastatic sites were bone, followed by
      lung, liver, and brain. Patients with hormone receptor+/human epidermal growth
      factor receptor 2- and hormone receptor+/human epidermal growth factor receptor
      2+ status were more prone to bone metastases. Lung and brain metastases were
      common in hormone receptor-/human epidermal growth factor receptor 2+ and hormone
      receptor-/human epidermal growth factor receptor 2- subtypes, and patients with
      hormone receptor+/ human epidermal growth factor receptor 2+ and hormone
      receptor-/human epidermal growth factor receptor 2+ subtypes were more prone to
      liver metastases. Patients with liver and brain metastases had unfavorable
      prognosis for breast cancer-specific survival and overall survival, whereas bone 
      and lung metastases had no effect on patient survival in multivariate analyses.
      The hormone receptor-/human epidermal growth factor receptor 2- subtype conferred
      a significantly poorer outcome in terms of breast cancer-specific survival and
      overall survival. hormone receptor+/human epidermal growth factor receptor 2+
      disease was associated with the best prognosis in terms of breast cancer-specific
      survival and overall survival. Patients with liver and brain metastases were more
      likely to experience poor prognosis for breast cancer-specific survival and
      overall survival by various breast cancer subtypes. Distant metastases sites have
      differential impact on clinical outcomes in stage-IV breast cancer. Follow-up
      screening for brain and liver metastases might be effective in improving breast
      cancer-specific survival and overall survival.
FAU - Wu, San-Gang
AU  - Wu SG
AD  - 1 Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated 
      Hospital of Xiamen University, Xiamen, People's Republic of China.
FAU - Li, Hui
AU  - Li H
AD  - 2 Huanghuagang Street Community Health Service Center, Guangzhou, People's
      Republic of China.
FAU - Tang, Li-Ying
AU  - Tang LY
AD  - 3 Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of
      Ophthalmology and Visual Science, Medical College of Xiamen University, Xiamen,
      People's Republic of China.
FAU - Sun, Jia-Yuan
AU  - Sun JY
AD  - 4 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, People's Republic of China.
FAU - Zhang, Wen-Wen
AU  - Zhang WW
AD  - 4 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, People's Republic of China.
FAU - Li, Feng-Yan
AU  - Li FY
AD  - 4 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, People's Republic of China.
FAU - Chen, Yong-Xiong
AU  - Chen YX
AD  - 3 Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of
      Ophthalmology and Visual Science, Medical College of Xiamen University, Xiamen,
      People's Republic of China.
FAU - He, Zhen-Yu
AU  - He ZY
AD  - 4 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Bone Neoplasms/*epidemiology/genetics/pathology/secondary
MH  - Brain Neoplasms/*epidemiology/genetics/pathology/secondary
MH  - Breast Neoplasms/*epidemiology/genetics/pathology
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*epidemiology/genetics/pathology/secondary
MH  - Lung Neoplasms/*epidemiology/genetics/pathology/secondary
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Receptor, ErbB-2
MH  - Receptors, Estrogen/genetics
MH  - Receptors, Progesterone/genetics
MH  - SEER Program
OTO - NOTNLM
OT  - Breast cancer
OT  - Epidemiology
OT  - Surveillance
OT  - and End Results
OT  - metastases
OT  - subtype
OT  - survival
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317705082 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317705082. doi: 10.1177/1010428317705082.